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Background: Semaphorin3A (Sema3A) is an axon guidance molecule present in the CNS extracellular matrix and on the
perineuronal nets (PNNs).
Results: Sema3A interacts with chondroitin sulfate E (CS-E) for anchoring to the PNNs.
Conclusion: The binding of Sema3A to CS in the PNNs presents a novel mechanism of PNNs in restricting plasticity.
Significance: This finding suggests a novel candidate for intervention in promoting CNS recovery.
Chondroitin sulfate (CS) and the CS-rich extracellularmatrix
structures called perineuronal nets (PNNs) restrict plasticity
and regeneration in the CNS. Plasticity is enhanced by chon-
droitinaseABC treatment that removes CS from its core protein
in the chondroitin sulfate proteoglycans or by preventing the
formation of PNNs, suggesting that chondroitin sulfate pro-
teoglycans in the PNNs control plasticity. Recently, we have
shown that semaphorin3A (Sema3A), a repulsive axon guidance
molecule, localizes to the PNNs and is removed by chondroiti-
nase ABC treatment (Vo, T., Carulli, D., Ehlert, E. M., Kwok,
J. C., Dick, G., Mecollari, V., Moloney, E. B., Neufeld, G., de
Winter, F., Fawcett, J. W., and Verhaagen, J. (2013) Mol. Cell.
Neurosci. 56C, 186–200). Sema3A is therefore a candidate for a
PNN effector in controlling plasticity. Here, we characterize the
interaction of Sema3A with CS of the PNNs. Recombinant
Sema3A interacts with CS type E (CS-E), and this interaction is
involved in the binding of Sema3A to rat brain-derived PNN
glycosaminoglycans, as demonstrated by the use of CS-E block-
ing antibody GD3G7. In addition, we investigate the release of
endogenous Sema3A from rat brain by biochemical and enzy-
matic extractions. Our results confirm the interaction of
Sema3A with CS-E containing glycosaminoglycans in the dense
extracellular matrix of rat brain. We also demonstrate that the
combination of Sema3A and PNNGAGs is a potent inhibitor of
axon growth, and this inhibition is reduced by theCS-Eblocking
antibody. In conclusion, Sema3A binding to CS-E in the PNNs
may be amechanismwhereby PNNs restrict growth and plastic-
ity and may represent a possible point of intervention to facili-
tate neuronal plasticity.
The perineuronal nets (PNNs)2 are dense extracellular
matrix structures that surround the soma and dendrites of
many neurons in themature CNS, in particular the GABAergic
interneuron in the cerebral cortex. PNNs are composed of
chondroitin sulfate proteoglycans (CSPGs), link proteins, hyal-
uronan, and tenascins (2, 3). PNNs appear relatively late during
development, at the end stage of refinement and consolidation
of the neuronal circuitry (4–6), coinciding with closure of the
critical period for plasticity (7, 8). PNNs have a structure similar
to cartilage. They contain aggrecan, neurocan, versican, and
brevican, which are CSPGs from the lectican family, and phos-
phacan, a surface-bound CSPG. The lecticans interact with
hyaluronan via their N-terminal link modules, and the interac-
tions are further stabilized by one or both of the link proteins,
cartilage link protein (Crtl1), and brain link protein 2 (Bral2) (3,
4, 9). The C terminus of the CSPGs also binds to tenascin-R,
producing a stable ternary structure. The degree of cross-link-
ing makes the PNN core components resistant to solubiliza-
tion, which requires 6 M urea (10). The CSPGs are extensively
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glycanated by chondroitin sulfate (CS) glycosaminoglycan
(GAG) chains. The GAG composition with respect to sulfation
differs between the PNN-associated GAGs and the GAGs
derived from themore soluble PGs in theCNS (10). Because the
binding properties of GAGs depend on their pattern of sulfa-
tion, this suggests that 2–3% of total brain CS-GAG chains
associated with the PNNs may have different binding affinities
than those in the free-floating matrix.
The interest in the PNNs stems from the evidence that they
are responsible for the restriction of plasticity in the CNS that
occurs at the end of the critical periods. Degradation of CS by
enzymatic treatment using chondroitinase ABC (ChABC) has
demonstrated remarkable enhancement in plasticity in the vis-
ual cortex (8) and in the injured CNS (11–13) and prolongation
ofmemory (14). The same enhancement of plasticity andmem-
ory is also observed in animals that lack Crtl1 in the CNS and
therefore have attenuated PNNs, indicating that ChABC pro-
motes plasticity through digestion of CS-GAGs in PNNs (9).
Although it is established that PNNs restrict plasticity, the
mechanism in which they do so is unknown. A possible mech-
anism involves semaphorin3A (Sema3A), which binds to neu-
ropilins on axons and synapses to affect axon growth and syn-
aptic change (15–17). Recent studies also suggest that Sema3A
mediates its effect by regulating local protein synthesis in axons
(18, 19). Sema3A is a guidance signal involved in several axon
guidance and neuronal migratory events during development
(20–22). However, the expression of Sema3A persists at a con-
siderable level in parts of the CNS into adulthood (23). Its pres-
ence affects synapse dynamics (15, 17) and may influence plas-
ticity in the mature CNS (22). An interaction between CS and
Sema3A has been previously reported in vitro in neuronal cell
culture (25) and also by co-localization studies of CSPG and
Sema3A during development in vivo (26). More recently, we
have shown that Sema3A is concentrated around PNNs in the
matureCNS and that it co-localizeswith several components of
the PNNs (1). Moreover, counteracting the effects of Sema3A
using decoy receptor bodies for neuropilin-1 partly restores
ocular dominance plasticity in the adult CNS, indicating that
Sema3A is a PNNeffector (27). Sema3A is bound there through
CS-GAGs in the PNNs because in vivo ChABC digestion
removes the Sema3A staining (1). Although ChABC may also
digest hyaluronan, to a much lesser extent, the binding of
Sema3A is specific toCS-GAGs. This is supported by the obser-
vation that an administration of Streptomyces hyaluronidase,
which is specific to hyaluronan digestion, into adult rat brains
did not solubilize the perineuronal Sema3A staining.
In this study, we further characterize the interaction between
Sema3A and various CS isoforms.We have studied the potential
of enhancing plasticity and regeneration by interfering with the
interaction using an anti-CS-E antibody, GD3G7 (28). We report
that Sema3A binds to CS-E units that contain disulfated E disac-
charides and in those extracted from the PNNs. This interaction
serves to bind Sema3A to the PNNGAGs, and the combination of
Sema3A and GAG is inhibitory to axonal growth.
EXPERIMENTAL PROCEDURES
Recombinant Sema3A—Sema3A constructs used in the
experiments were described previously (25, 29). Recombinant
proteins of alkaline phosphatase (AP) fused to chicken collap-
sin-1 (Sema3A-AP) or green fluorescent protein (GFP) fused to
rat semaphorin3A (Sema3A-GFP), as depicted in Fig. 1, were
expressed in HEK 293T cells cultured in DMEM supplemented
with 10% FCS, penicillin (100 IU/ml), and streptomycin (100
g/ml; all from Invitrogen). Recombinant Sema3A proteins
were derived from media or cell lysate of the transfected HEK
cells. Transfections of plasmids were performed by Amaxa
(Lonza, Switzerland), according to the manufacturer’s instruc-
tions, followed by a collection of conditioned media and cell
lysates after 24 h. Media were concentrated 5–10 times using
Microcon (3 kDa molecular mass cutoff) filter devices (Milli-
pore, MA). Detection of the expressed Sema3A-AP or -GFP
was done by slot blot orWestern blot analysis. Sema3A-Fc used
in the microarray assay was purchased from R&D Systems.
Tissue Extraction fromMouse Brains—Fractionation of brain
tissue was performed using the procedure in Refs. 10, 30 with
minor modifications. Adult mice were sacrificed and decapi-
tated. The brains were removed and stored at 70 °C. On the
day of extraction, one brainwas thawed in buffer 1 (1TBS, pH
7.0, with Complete Mini protease inhibitors) (Roche Diagnos-
tics) and homogenized on ice using a tight-fitting Potter-Elve-
hjem homogenizer. The homogenate was then centrifuged at
20,000  g for 30 min at 4 °C to separate nonsoluble material
(pellet) from the soluble material (supernatant). The homoge-
nization and subsequent centrifugation were repeated twice,
and the supernatants were pooled and termed extract 1. The
subsequent extractions with buffer 2 (buffer 1  0.5% Triton
X-100), buffer 3 (buffer 2  1 M sodium chloride (NaCl)), and
buffer 4 (buffer 3  6 M urea) were carried out by the same
procedure with a minor modification. Instead of using the
homogenizer, a pipette was used to gently resuspend the mate-
rial in the pellet to facilitate extraction as follows: extract 1
contains soluble molecules; extracts 2 and 3 contain mem-
brane-associated molecules, and extract 4 contains dense
matrix-associated molecules. Protein measurements of the
extracts were carried out using the Total Protein kit, Micro
Lowry, Peterson’s Modification (Sigma), or BCA protein assay
(Pierce/Thermo Scientific).
Isolation and Purification of PGs and GAGs from Rat Brains—
PGs and GAGs were isolated from extracts 1–4 of adult rat
brains (five brains per extraction) with slight modifications of
the procedure described in Refs. 10, 30. Extracts 1–4 were dia-
lyzed against low salt ion-exchange buffer (50 mM Tris, pH 7.5,
2 M urea, 0.2 M NaCl), filtered, and subjected to DEAE ion-
exchange chromatography (GE Healthcare). Bound PGs were
eluted using high salt ion-exchange buffer (low salt buffer 1M
NaCl). The high salt PG eluate was dialyzed against 1 PBS, pH
7.0, and divided into two parts as follows: one for PG isolation
using ethanol precipitation (95% ethanol, 1.3% potassium ace-
tate, CH3COOK) or subjected to further GAG purification as
described previously (10, 30). The final GAG extracts were
termed according to the initial brain extraction as follows: sol-
uble GAGs (originating from extract 1), detergent GAGs
(extracts 2 and 3), and PNN GAGs (extract 4). The GAG con-
centration in the extracts was determined by Blyscan assay
(Biocolor, UK).
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Enzymatic Release of Sema3A from Rat Brain—To test for
the release of Sema3A from the PNNs, adult rat brain was
homogenized in appropriate enzyme buffers and divided into
enzyme and nonenzyme incubations. The samples were
digested with 100 milliunits of ChABC (EC 4.2.2.4), chondro-
4-sulfatase (EC 3.1.6.9), or chondro-6-sulfatase (EC 3.1.6.10) in
0.1 M NH4Ac, pH 8.0 (all enzymes were isolated from Proteus
vulgaris andwere purchased fromSeikagakuCorp., Japan). The
reactions were incubated at 37 °C overnight. Hyaluronan diges-
tion was done by adding 100 turbidity reducing units/ml
hyaluronidase (EC 4.2.2.1) from Streptomyces hyalurolyticus
(Seikagaku Corp., Tokyo, Japan) in 0.15 M NaCl, 0.02 M acetate
buffer, pH 6.0. Heparan sulfate (HS) digestion was done using
25 milliunits each of heparitinase I (EC 4.2.2.7) and III (EC
4.2.2.8) from Flavobacterium heparinum in 0.05 M sodium ace-
tate, 5 mM calcium acetate buffer. Both enzymes were pur-
chased from Sigma. Sema3A released from the brain homoge-
nate was determined by Western blotting of the supernatant
after centrifugation (as in the extraction procedure) and pre-
sented as the ratio of the band intensity between the Sema3A in
the enzyme-digested sample, and normalized it to the nonen-
zyme-treated sample.
ELISA—The ELISA was modified from Ref. 28. Biotinylated
GAGs, 0.5 or 2.0 g per well, were immobilized onto streptavi-
din-coated plates of 384 or 96 wells (Pierce/Thermo Scientific).
CS variants and HS were purchased from Seikagaku Corp.
(Japan), and CS-A was isolated from whale cartilage; CS-B was
from pig skin; CS-C and CS-D were from shark cartilage, CS-E
was from squid cartilage; HS was from bovine kidney, and hep-
arin was from porcine intestine. The basic disaccharide units
from the different CS variants are shown in Fig. 1B. Although
the biotinylated heparin was purchased from Sigma, the brain-
derived GAGs were extracted and purified as described above.
Biotinylation of GAGs was performed by EDC and biotin-LC-
hydrazide conjugation (Pierce/Thermo Scientific). After GAGs
were immobilized on the plates, the plates were blocked in 1%
BSA and subjected to the binding of recombinant Sema3A-AP
(or -GFP) in 1:5 to 1:8 dilutions. Detection of Sema3A-AP was
done by direct measurement of absorbance at 405 nm using
p-nitrophenyl phosphate (Sigma). To detect binding of
Sema3A-GFP, the wells were incubated with 1:2,000 rabbit
anti-GFP antibody (Abcam), or 1:2,000 rabbit anti-Sema3A
antibody (Abcam), and subsequently with 1:10,000 AP-conju-
gated anti-rabbit antibody (Invitrogen). Detection was done by
measuring the absorbance at 405 nmusing p-nitrophenyl phos-
phate. The indirect ELISA was performed in a similar fashion,
and the recombinant Sema3A-APwas incubated with the com-
peting GAGs or blocking antibody at room temperature for 30
min before being transferred to the wells that were all coated
with biotinylated heparin. While the phage display antibody
GD3G7 is specific to CS-E (28), the control antibody MPB49V
does not bind to any CSs.
Carbohydrate Microarray Assays—Microarrays containing
natural GAGs enriched in the CS-A, CS-C, CS-D, and CS-E
motifs (Seikagaku Corp.), dermatan sulfate (also called CS-B;
Sigma), hyaluronic acid (HA; Sigma), heparin (Hep; Neoparin,
Alameda, CA), HS (Sigma), or chondroitin sulfate (CS; Sigma)
were printed on poly-D-lysine-coated glass surfaces as
described previously (31, 32). Arrays were blocked with 10%
FBS in 1 PBSwith gentle rocking at room temperature for 1 h,
followed by a brief rinse with 1 PBS. Sema3A-Fc (R&D Sys-
tems, Minneapolis, MN) was reconstituted in 1% BSA in 1
PBS, added to the slides (100 l at a concentration of 2 M per
slide, and incubated at room temperature for 3 h. The slides
were briefly rinsed three timeswith 1 PBS and then incubated
with a 1:5,000 Cy3-conjugated goat anti-mouse IgG antibody
(Jackson ImmunoResearch,West Grove, PA) for 1 h in the dark
with gentle rocking. The microarrays were then washed (three
times of 1 PBS and two times with de-ionized water), dried
under a stream of air, and scanned at 532 nm using a GenePix
5000a scanner. Fluorescence quantification was performed
using GenePix 6.0 software (Molecular Devices, Sunnyvale,
CA). Experiments were performed in triplicate, and the data
represent the average of 10 spots per concentration averaged
from the three experiments (S.E., error bars).
Western Blot and Slot Blot Assay—12g of protein fromeach
brain extractwas subjected to SDS-PAGEandWestern blotting
using the NuPAGE system (Invitrogen). Primary antibodies
used were against Sema3A (1:2,000, Abcam) and Crtl1 (1:2,000,
R&D Systems). Secondary antibodies used were anti-rabbit-
HRP (1:50,000, GE Healthcare) and anti-goat-HRP (1:3000,
Vector Laboratories). Detection of Western blots was done
using ECL (GEHealthcare). In the dot blot, 0.3, 1, and 3g of
CS-E andCS-B in 1 PBS, or 1, 5, and 10g of bovine aggrecan
(Sigma) in 1 PBS were applied to nitrocellulose membrane
(GE Healthcare). Anti-CS-E antibody GD3G7 was added in
1:400 dilution to the membrane. This antibody contains a
VSV-G tag, which was used for detection. After washes, anti-
body against VSV-G tag P5D4 (1:20,000, Abcam) was added.
The blot was subsequently probed with anti-mouse HRP anti-
body (1:50,000, GE Healthcare). Detection was done using
ECL (GE Healthcare).
Lectin Histochemistry—Fresh frozen sagittal sections from
adult rat brain (15m)were first labeled with biotinylatedWis-
teria floribunda agglutinin (WFA, 5 g/ml; Sigma) and then
with Alexa Fluor-488-streptavidin (1:2,000; Invitrogen). The
sections were subjected to 20-min washes of buffers as
described for the extraction of GAGs from brain tissue. Post-
wash fixation was done in 3% paraformaldehyde. Histochemi-
cal staining was performed as described previously (10). Fluo-
rescence imaging was captured with conventional fluorescence
microscope.
Co-immunoprecipitation—PNN PGs isolated from extract 4
as described above were incubated with or without recombi-
nant Sema3A-GFP lysate, also described above. 30 l of
Sema3A-GFP lysate was added to 300l of PNNPG solution in
the presence of 1:300 rabbit anti-GFP antibody (Abcam). After
1 h of incubation, 30 l of protein-A magnetic beads (Invitro-
gen) were added. Washes and magnetic separation were per-
formed according to manufacturers’ protocol. To analyze the
CS-dependent Sema3A-GFP retention of CSPGs, magnetic
beads were treated with ChABC (as before) followed by West-
ern blot analysis (as described above). CSPGs retained by
Sema3A-GFP and released by ChABC digestion was detected
using 1:2,000 of mouse monoclonal 2-B-6 antibody (Seikagaku
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Corp.), which is specific against the digested glycan stump after
ChABC digestion of CS GAG chains.
Dorsal Root Ganglia (DRG) Outgrowth Assay—DRGs were
dissected from Sprague-Dawley rats (3 months). Each gan-
glion was then cut into 4–6 smaller explants. To determine the
inhibitory effect of Sema3A, 100 l of a mixture of Sema3A
(1:10, 100, and 1,000) and 1 g/ml laminin was coated on the
glass coverslips for 1 h at room temperature. To test for the
efficiency of GD3G7 or various GAG-degrading enzymes in
blocking Sema3A from binding to the PNN-GAGs, isolated
PNN-GAGswere added to the coverslips together with laminin
for 30 min and then rinsed briefly with sterile 1 PBS. GD3G7,
MPB49V, and various GAG lyases were then added to the cov-
erslips and incubated for 30 min at room temperature. The
coverslips were rinsed three times with sterile 1 PBS before
the addition of 1:10 Sema3A for 30 min at room temperature.
The coverslips were rinsed again before the ready-cut explants
were plated on the coverslips. The explants were cultured in
DMEM supplemented with insulin/transferrin/selenium (1),
penicillin/streptomycin/fungizone (1), and 10 ng/ml nerve
growth factor for 2 days at 37 °C, 5% CO2. To quantify the
axonal outgrowth, DRG explants were immunostained for III
tubulin for their neurites. The 10 longest neurites from each
explant were measured and averaged using the Leica Applica-
tion Suite (Leica Microsystems). The average neurite length
was then calculated from all the explants on each coverslip to
give a final measurement for each condition. In some experi-
ments, the number of neurites per explant was quantified, and
the explants were grouped accordingly into three different
classes (3 or less neurites, 4–19 neurites, 20 or more neurites).
RESULTS
Our previous work has demonstrated that Sema3A is con-
centrated on the PNNs and is removed by ChABC treatment
implying that it is bound to the GAG chains of CSPGs (1). To
study if Sema3Abinds specifically to individual CS isoforms, we
have characterized the binding of Sema3A to different defined
CS and HS structures and to glycans extracted from the adult
CNS.
Sema3A Interacts with CSGAGs—To investigate the binding
of Sema3A to immobilized CS preparations with known sulfa-
tion patterns, we used twomethods, ELISA (both a direct and a
competitive ELISA) and GAG microarray. To minimize the
possible interference of different tags on Sema3A binding, we
used three variants of recombinant Sema3A to consolidate the
results (Fig. 1). Sema3A-AP is a fusion protein with an N-ter-
minal AP sequence fused to chick Sema3A (also called collapsin
1), which lacks its intrinsic signal sequence (29). Sema3A-GFP
is modified by an insertion of GFP between the Sema3A signal
sequence and the downstream domains, as described previ-
ously (25). Sema3A Fc is a purified Sema3A protein fused with
a His tag at the N terminus and a human IgG peptide at the C
terminus. Initially, we screened for direct binding of Sema3A to
various CS GAGs, as well as HS and heparin (Fig. 2A). Sema3A
interacted specifically with CS-E (enriched in 4,6-disulfated
disaccharide units) and displayed very strong binding to hepa-
rin. To minimize possible interference or masking of binding
sites by biotin, we confirmed these results using a competitive
ELISA. Biotinylated heparin was immobilized to the plates, and
untagged CS GAGs were assayed for their ability to block the
strong interaction of Sema3Awith the bound heparin (Fig. 2B).
Similar to the direct binding experiment, the results demon-
strated that in the presence of CS-E, less Sema3A interacted
with the immobilized heparin in the wells. This suggests that
Sema3A interacts with CS-E, which competes with Sema3A
binding to heparin (Fig. 2B, 5th and 7th bars). Competitive
binding was also seen with CS-B (Fig. 2B, 2nd bar) and to a
lesser extent with CS-A (4-sulfated) and HS (1st and 6th bars).
CS-C (6-sulfated) and -D (rich in 2,6-disulfated units) did not
affect Sema3A binding to heparin (Fig. 2B, 3rd and 4th bar).
This shows that the binding of Sema3A to GAGs is specific to
their sulfation pattern rather than on the overall number of
sulfate groups on the GAGs.
To further characterize the interactionswithCS-B and -E,we
tested the binding of Sema3Awith increasing concentrations of
CS-B, -C, and -E in a competitive ELISA. Both CS-B and -E
competed strongly with heparin binding at all the concentra-
tions tested, but there was aminimal effect with CS-C (Fig. 2C).
The binding interactions of CS-B and -E were indistinguish-
able. We also employed a different recombinant variant of
Sema3A to discount the effects of the AP tag on the binding.
Repeating the experiments using Sema3A-GFP-containing
lysate reproduced the same binding patterns (data not shown).
To verify that this binding is due to a specific interaction of the
expressed Sema3A but not other contaminating proteins pres-
ent in the partially purified Sema3A, we compared the binding
affinity to heparin using cell lysate recovered from Sema3A-
GFP-expressing cells and non-Sema3A-expressing cells (Fig.
2D). Although the lysate from Sema3A-GFP-expressing cells
FIGURE 1. A, schematic diagram of the differently tagged Sema3A fusion pro-
teins used in this study. For chicken AP-collapsin 1, the AP was fused to the
N-terminal part of chicken collapsin 1 lacking a signal sequence (SS) (29). For
rat GFP-semaphorin 3A, the GFP was inserted after the N-terminal signal
sequence in the rat Sema3A sequence (24). Sema3A-Fc is procured from the
R&D Systems and contains a His tag at the N terminus and a C-terminal Ig
sequence. B, chemical structures of the various GAGs used in this study.
Semaphorin3A Interacts with CS-E in PNNs
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bound strongly to the heparin (Fig. 2D, 1st bar), the binding of
the control cell lysate was as weak as the negative “no lysate”
control (2nd and 3rd bars).
To further consolidate this specific interaction of Sema3A to
CS-E and heparin, we also employed a carbohydratemicroarray
to examine the binding of Sema3A to various CS GAGs
enriched in specific sulfation motifs, as well as CS-B, HA, hep-
arin, and HS (Fig. 2E). This method allows a direct comparison
of protein binding across diverse GAG classes enriched in spe-
cific sulfation motifs. Sema3A exhibited a strong, concentra-
tion-dependent binding to CS-E and heparin, with weaker
binding to CS, a GAG preparation that contains multiple sulfa-
tion motifs. Little or no binding to CS-A, CS-C, or CS-D was
observed, highlighting the specificity of Sema3A for the CS-E
sulfation motif.
Sema3A Interacts with GAGs from the PNNs via Its Interac-
tion with CS-E—We then characterized the interactions of
Sema3A with the GAGs isolated from adult rat brains. In pre-
vious work, we have developed a sequential extraction method
to separate PNN GAGs from the soluble or membrane-at-
tached GAGs. These sequential fractions contain GAGs with
different sulfation patterns suggesting different binding prop-
erties (10). TheGAGs recovered from the sequential extraction
were biotinylated and immobilized on streptavidin-coated
plates. Sema3A demonstrated a strong and specific binding
affinity toward the PNNGAGs but showed little binding to the
soluble and membrane-bound GAGs (Fig. 3A). We have previ-
ously demonstrated that the PNN GAG fraction contains
70%CS and30%HS (9). To examine if the binding is due to
the presence of CS or HS, we treated the GAG solution with
ChABC, heparitinases I and III, or a combination of the
enzymes in a competitive ELISA.The enzymeswere inactivated
by incubation at 70 °C, after which we tested for the Sema3A
binding (Fig. 3B). Digestion by either ChABC or heparitinases
alone gave only a modest reduction in the ability of the PNN
GAGs to compete for Sema3A binding to immobilized heparin
(Fig. 3B, 2nd to 4th bars; p 0.05).However, when both types of
enzymes were used together, Sema3A binding was abolished
(bar 5). This suggests that both CS and HS GAGs in the PNNs
may contribute to the binding of Sema3A.
The structure of the CS GAGs derived from PNNs contains
2% of the CS-E units and 0.8% of the CS-B (2,4-disulfated)
FIGURE 2. Sema3A demonstrates preferential binding to CS-E and CS-B. Recombinant Sema3A-AP was used in direct (A) and competitive (B and C) ELISA
toward various CS GAGs. A, although Sema3A-AP interacts very specifically with heparin and CS-E, it does not bind to other CSs. The binding affinity was
determinedbyAP activitymeasured at absorbance at 405 nm, n 4,mean S.D. B, Sema3A-AP interactionwith heparin in competitionwith various CSGAGs,
HS, and heparin. The binding of Sema3A to heparin was inhibited after incubation with CS-B, CS-E, and heparin. The binding was determined by AP activity
measured at 405 nm. Competitive inhibition presented as percentage of binding in relation to reading in Sema3A-AP only sample (equals 100%binding), n
4, mean S.D. C,measurements of dose-dependent inhibition of various concentrations of CS-B, CS-C, and CS-E in blocking Sema3A-AP interaction toward
heparin in a competitive ELISA. BothCS-BandCS-E inhibit thebindingof Sema3A toheparin,whereasCS-Cdoesnot.Determinationof Sema3A-APbindingand
presentation as in B, n  3, mean  S.D. D, control experiment measuring binding to heparin using lysate from Sema3A-GFP-transfected cells, lysate from
non-transfected (Cntrl lysate), and no lysate. Note that Sema3A-GFP cell lysate interacted very strongly to the immobilized heparin, whereas the control lysate
gave similar signal level as the negative control “no lysate.” This suggests that the binding of Sema3A-GFP to heparin is due to the expressed Sema3A in the
lysate but not other protein contaminants. Binding affinity was measured and presented as absorbance at 405 nm, n 3, mean S.D. E, Sema3A-Fc binds
selectively to CS-E-enriched polysaccharides on GAG microarrays. Microarrays containing different concentrations (0.5, 1, and 5 M) of the indicated GAG
polysaccharides were incubated with Sema3A-Fc, followed by a Cy3-conjugated anti-mouse IgG secondary antibody, and analyzed using a Gene-Pix 5000A
scanner. Data represent the mean S.E. from three experiments (n 10 per condition). CS-A is 4-sulfated, CS-B is 2,4-disulfated, CS-C is 6-sulfated, CS-D is
2,6-disulfated, and CS-E is 4,6-disulfated.
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(10). Despite the low proportions of these disulfated forms, the
preceding results suggest that they may be responsible for the
specific binding of Sema3A to the PNN structure. To specifi-
cally target CS-E interactions, we utilized a specific blocking
antibody, GD3G7. This phage display antibody recognizes CS-
E-containing epitopes in the developing brain (28). We first
confirmed the specificity of the antibody in a slot blot assay
against CS-B, CS-E and bovine aggrecan (Fig. 4A). We found
that GD3G7 binds specifically to CS-E but not CS-B, and binds
to bovine aggrecan. Aggrecan is a CSPG which bears multiple
CS-GAG chains, the GD3G7 antibody is probably recognizing
the CS-E units present in aggrecan’s GAG chains. We then
investigated the antibody’s ability to block the interaction of
Sema3A with CS-E and with PNN GAGs. Addition of GD3G7
reduced the binding of Sema3A to immobilized CS-E by 68%
(Fig. 4B). The GD3G7 antibody also blocked Sema3A from
binding to brain-derived PNN GAGs by 65% (Fig. 4C) and in a
concentration dependent manner (Fig. 4D). In comparison to
the control phage displayed MPB49V antibody, GD3G7 was
more effective in blocking Sema3A binding to PNNGAGs over
a range of concentrations.
Release of Endogenous Sema3A from Rat Brain by Biochemi-
cal and Enzymatic Extraction—Our previous work has shown
that Sema3A localizes to the PNN structures in the brain (1).
Although the PNNs are distributed in several areas in the rat
brain, in the cerebral cortex, PNNs are mainly associated with
GABAergic interneurons (33, 34). Sema3A co-localizationwith
PNNs was particularly strong in layers IV and V in the cerebral
cortex and was mainly associated with parvalbumin-positive
interneurons (1). To characterize Sema3A binding to the
PNNs, we performed our sequential extraction procedure on
adult rat cortical sections, monitoring the release of Crtl1 and
Sema3A at each step (Fig. 5). As in our previous work (10), the
PNNs and PNN GAGs remained in place through the extrac-
tion in 1 TBS, 0.5% Triton X-100, and 1 M NaCl (Fig. 5A), as
demonstrated by WFA staining. Intact PNNs was observed
after the 1TBSwash. After the washes with TritonX-100 and
1 M NaCl, the staining in the neurites was weakened (arrow-
heads in Fig. 5A), but the intensity on the soma remained the
same (arrows in Fig. 5A). We could not performWFA staining
in the cortical sections after 6Mureawash due to the poor tissue
integrity. However, to investigate if Sema3A is released after
PNNs were dissolved in 6 M urea buffer, we continued to mon-
itor the release of Sema3A and Crtl1 (a key molecule in consol-
idating PNNs) using Western blot. Only with the wash in 6 M
urea did the CNS tissues release the majority of the Crtl1 pro-
tein, suggesting the dissolution of the PNNs (Fig. 5B, left panel).
The binding of Sema3A to the PNNs is weaker than that of the
Crtl1. The majority of Sema3A was released by the addition of
FIGURE 3. Sema3A binding to GAGs extracted from adult rat brain dem-
onstrates high binding affinity to PNN GAGs. Recombinant Sema3A-AP
binding to brain GAGs in direct (A) and competitive ELISA (B). A, Sema3A-AP
binds with high affinity to PNN-GAGs but not to the soluble GAGs or deter-
gent GAGs in a direct ELISA. Binding affinity was determined by AP activity
measured and presented as absorbance at 405 nm, n  3, mean  S.D. B,
PNN-GAGs (with and without ChABC or Hep I and III treatment) was preincu-
bated with the Sema3A-AP before adding onto heparin-coated wells in an
indirect ELISA. The binding of Sema3A alone is defined as 100% (1st bar).
Incubation with PNN GAGs decreases the binding to 20% (2nd bar). Pre-
treatment of the PNNGAGswith ChABC (3rd bar) or Hep I and III (4th bar) only
partially removes the inhibition. However, co-treatment of both ChABC and
heparitinases restores the Sema3A-AP binding to the immobilized heparin,
Bindingaffinity determinedbyAPactivitymeasuredas absorbance at 405nm
and presented as a percentage of binding relative to reading in Sema3A-AP
only sample (equals 100%), n 4,mean S.D., two-tailed paired t test: *, p
0.05, ***, p 0.001.
FIGURE 4. Sema3Abinding to PNNGAGs is inhibitedbyblocking theCS-E
structure. A, slot blot assay using anti CS-E phage display antibody GD3G7
(26) toward CS-E, CS-B, and bovine aggrecan. The result demonstrates that
although the GD3G7 antibody specifically recognizes CS-E and detects a CS-
E-like structure in aggrecan, it does not bind to CS-B. B and C, ELISA of
Sema3A-AP interaction toward CS-E and PNN GAGs, with and without the
addition of anti-CS-E antibody GD3G7. GD3G7 effectively blocks the binding
of Sema3A-AP to both CS-E and PNN GAGs by 60%. Binding affinity was
determinedbyAP activitymeasured andpresented as absorbance at 405nm,
n  3, mean  S.D. D, a direct ELISA of Sema3A-AP interaction toward PNN
GAGsas inCusingvarious concentrationsofGD3G7andanonspecific control
phage display antibodyMPB49V. It shows a concentration-dependent block-
ing of GD3G7 toward Sema3A-AP binding to the PNN-GAGs. n 3, mean
S.D.
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detergent, 0.5% Triton X-100 (Fig. 5, right panel). Both the full-
length (95 kDa) and N terminus of processed Sema3A (65
kDa) could be observed in this extract. However, it is important
to note that the Sema3A remains bound at physiological con-
ditions (50 mM TBS) and is retained at the cell surfaces as
described in several in vitro studies (25, 35).
We next investigated the nature of the interaction between
endogenous Sema3A and PNNs using high salt and GAG lyase
digestions to modify the GAGs, while measuring the release of
Sema3A from brain tissue. Treatment with 1 M NaCl released
Sema3A from rat brains, indicating that the binding is partly
dependent on ionic interactions, as with other GAG-protein
interactions (Fig. 6A). To further analyze the nature of GAGs
involved in the interaction, brain homogenates were treated
with enzymes specifically degrading hyaluronan,CS, orHS (Fig.
6B). ChABC treatment increased the release of Sema3A into
the soluble fraction, whereas degradation of other GAGs did
not (Fig. 6, B and C). Although ChABC to some extent acts on
hyaluronan, the fact that hyaluronidase digestion did not
release Sema3A implies that CS GAGs is the major binding
partner in the brain extracellular matrix. The in vitro binding
assay described in Fig. 2 indicates that Sema3A binds to CS
GAGs containing di-sulfated disaccharides (CS-E and CS-B).
This is consistent with our finding on sulfatase digestion here.
Using chondro-4- or -6-sulfatase, we demonstrated that the
removal of 6-sulfate from CS GAGs released Sema3A to the
same extent as ChABC (Fig. 6, B,middle panel, and C, 2nd and
3rd bar). CS-E chains containing 4,6-di-O-sulfated E-units are
digested by chondro-6-sulfatase, and it appears that the
chondro-6-sulfatase removes the 6-O-sulfate groups from the
4,6-disulfated GalNAc in the CS-E units, creating the 4-O-sul-
fated GalNAc to which Sema3A does not bind. It has been
reported that chondro-6-sulfatase removes a 6-O-sulfate group
from both GalNAc-6-sulfate and GalNAc-4,6-di-O-sulfate
units (36). The chondro-4-sulfatase, which has been reported to
remove 4-O-sulfate groups from GalNAc-4-O-sulfate even
from the internal positions under harsh conditions (37) and
does not act on GalNAc-4,6-di-O-sulfate (-E unit) (38), did not
release Sema3A. The release data are consistent with Sema3A
binding to CS-E in the PNNs.
Sema3A Interacts with a Large CSPG in the PNNs—ThePNN
matrix consists of several PGs carrying CS GAG chains. To
investigate if the CS-E that binds Sema3A resides on a specific
PG, we performed a co-IP of Sema3A after incubation with
PNN PGs. Sema3A-GFP lysate was incubated with the PNN
FIGURE 5. Solubilization of PNNs, CRTL1, and Sema3Awith different buf-
fers fromadult rodentbrains.A, adult rat cortical sectionswere sequentially
washedwith buffers of increasing denaturing power and stainedwith biotin-
ylatedWFA PNNs. Treatment with Triton X-100 (Tx-100) and 1 M NaCl leads to
a decrease in the WFA staining in the neurites (arrowheads) but not on the
soma (arrows). Scale bar equals 50m.B,Westernblot of thebuffers collected
after the sequential extraction frommousebrainhomogenates. Although the
majority of CRTL 1 is released with 6 M urea buffer, most of the Sema3A is
released with Triton X-100 buffer, to amuch lesser extent in the 1 M NaCl or 6
M urea buffers.
FIGURE 6. Release of Sema3A frombrain tissue after enzymatic degrada-
tion of GAG chains. The released Sema3A was detected by Western blot of
the extracted soluble fractions after enzyme treatment.A, Sema3A is released
withhigh salt (1 MNaCl)wash.B,whereas digestionwithChABCand chondro-
6-sulfatase causes an increase in the release of Sema3A from the brain tissue,
digestion of hyaluronan using hyaluronidase, chondro-4-sulfatases on CS-A,
andHep I and III does not increase the release Sema3A (C) or quantification of
the signal in the Western blots in B. Relative release is presented as a ratio of
Sema3A signal from the enzyme-treated brain homogenate against the non-
enzyme-treated samples,n2–4,meanS.D., two-tailedpaired t test: *,p
0.054; **, p 0.01.
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PGs isolated from extract 4 (the PNN fraction), followed by IP
against the GFP part of Sema3A using anti-GFP antibody.
Sema3A-GFP lysate was used in this experiment due to a pro-
teolytic cleavage of Sema3A-GFP by the normal cellular pro-
cess, and full-length Sema3A-GFP can only be recovered in cell
lysate instead of culture media (Fig. 7, A and B). After incuba-
tion with the anti-GFP antibody, the Sema3A-GFPPNN-PG
complex was pulled down by protein A magnetic beads. CSPG
was then released by ChABC treatment and analyzed byWest-
ern blot (Fig. 7C). We were able to detect a large core protein
with the use of an antibody (clone 2-B-6) recognizing the stubs
of the CS GAG chains that are left behind following ChABC
treatment (39). The size of the CSPG protein core that was
pulled down corresponds to aggrecan. However, by blotting
with antibodies directed against epitopes in the protein part of
aggrecan, we were not able to detect the band. The discrepancy
could be due to a difference in sensitivity. As the aggrecan has
multiple attachment sites for GAG chains (up to 100), the
ChABC-treated protein core probably contains multiple “stub”
epitopes that the 2-B-6 antibody can bind, although the
epitopes in the protein core are fewer and with variable affinity.
PNN GAGs and Semaphorin 3A Inhibits Adult DRG Out-
growth—Both Sema3A and CSPGs are associated with axon
growth inhibition in the adult nervous system. It is probable
that parts of PNNs’ capacity to reduce plasticity are based on
the inhibition from CSPGs in restricting axon growth, which is
potentiated by Sema3A binding. To determine the biological
function of our biochemical findings, we assessed the growth
inhibitory properties of PNN GAGs, Sema3A and the two
together in an in vitro assay using DRG neurons. To investigate
substrate-mediated effects, we first coated the coverslips with
laminin and subsequently with Sema3A and/or PNN-GAGs,
and DRG explants were then cultured on these substrate-
coated coverslips, and the neurite extension was assayed. DRG
explants cultured on 25 g/ml PNN-GAGs extended both
shorter (50% shorter) and fewer neurites compared with
laminin alone (Fig. 8, A and B). The addition of Sema3A on
PNN-GAGs further suppressed the neurite outgrowth from the
DRGs. A dose-dependent inhibition was observed when
increasing concentrations of Sema3A (at 1:100, 50, and 10 dilu-
tion) were used (Fig. 8,A andB). A combination of Sema3A and
PNN-GAGs led to an 80% decrease in the neurite length when
compared with laminin alone, a further 30% lower than when
PNN-GAGs/laminin was used. Similarly, this Sema3A (1:50)/
PNN-GAGs combination decreased the number of neurites
extending from the explants (Fig. 8B). The data imply that there
is an additive effect of Sema3A and PNN-GAGs in inhibiting
neurite initiation (Fig. 8B) as well as outgrowth (Fig. 8A).
We have previously shown that CS-E is enriched in the PNN-
GAGs (10), and to investigate the role of CS-E in this inhibition,
we cultured the DRGs in the presence of anti-CS-E antibody.
We chose to culture the DRG explants in 1:50 Sema3A with 15
g/ml PNN GAGs in subsequent experiments based on the
above result. Again, we observed a greater inhibition with
Sema3A and GAGs together than with either alone (Fig. 8, C,
and 3rd, 4th, and 5th bars in D). Enzymatic removal of CS-
GAGs using ChABC completely abolished the inhibition from
PNN-GAGs/Sema3A,whereasHep I and III treatment partially
reversed the inhibition (Fig. 8, bar 5 and 6). To investigate if
CS-E is involved in this neurite outgrowth inhibition, wemeas-
ured neurite growth on the combination of Sema3A and PNN-
GAGs in the presence of the anti-CS-E antibody GD3G7.
Whereas the addition of anti-CS-E antibody partially neutral-
ized the additive inhibition from Sema3A/PNN-GAGs, the
control antibody did not relieve the inhibition (Fig. 8, 7th and
8th bar).
DISCUSSION
This study was inspired, based on extensive data from us and
others, by the importance of PNNs in controllingCNSplasticity
and the effectiveness of ChABC in restoring plasticity and
recovery after removing the PNNs in the damaged nervous sys-
tem. The mechanism by which PNNs control plasticity is not
known, but our observation of Sema3A binding to the PNNs
suggests that presentation of Sema3A by PNNs to synapses and
axonal sprouts could be a key role of CSPGs in the PNNs.
Sema3A Binds to CS-E in PNNs—Sema3A is a potent regula-
tor of neurite growth (22) and cell migration (40) in the devel-
oping nervous system, and it has strong effects on synapse
dynamics (15–17). Cell surface retention of Sema3A has been
observed onNeuro-2a cells, fromwhich it is released byChABC
treatment or an addition of CS-B or heparin; this implicated
FIGURE 7. Co-immunoprecipitation (co-IP) of brain CSPG(s) with Sema3A-
GFP. A and B, full-length Sema3A-GFP recovered from cell lysate binds to hepa-
rin. Recombinant Sema3A-GFP in media and cell lysate were analyzed byWest-
ernblotting (WB) (A) andused in direct ELISA (B).A,Westernblottingof collected
cell media and lysate from Sema3A-GFP-transfected cells. N-terminal (65 kDa)
and full-length recombinantSema3A-GFP (95kDa)weredetectedbyanti-GFPor
anti-Sema3A antibody. This suggests that the recombinant Sema3A-GFP is
cleaved by normal cellular processing giving a fragment corresponding to the
wildtype65kDaN-terminal fragment (25).B,direct interactionwithSema3A-GFP
in media and lysate toward heparin. Because of extensive cleavage of the
secreted Sema3A-GFP, we applied conditioned media as well as lysate in the
ELISA. Binding toheparin-coatedwellswasdetectedwhenusing the lysate, con-
tainingmainly full-length Sema3A-GFP. Binding affinity wasmeasured and pre-
sentedasabsorbanceat405nm,n3,meanS.D.C,PNNPGs isolated fromthe
adult rat brainwas incubatedwith andwithout Sema3A-GFP lysate (1st and 2nd
lanes), followedby IPagainstGFPusinganti-GFPantibodyonproteinAmagnetic
beads. The beads were then treatedwith ChABC, and the supernatant was ana-
lyzedusingSDS-PAGEandWesternblotassay. 2-B-6antibodywasused todetect
the stubon the releasedCSPG(s) after the enzyme treatment. Twobands slightly
smaller than 460 kDa observed in the Sema3A-treated samples suggest that
Sema3A-GFP is binding to one (or more) high molecular weight CSPG(s) in the
brain homogenates. The size of the band suggests that the CSPGs could be
aggrecan. 5%of the inputwasaddedasacontrol after chondroitinase treatment
(3rd lane).
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FIGURE 8. Combination of Sema3A and PNN-GAGs confers a stronger inhibition on DRG culture that is alleviated with anti-CS-E antibody. Substrate
inhibition of DRG-neurite outgrowth by PNN GAGs and Sema3A. Adult rat DRG explants were cultured on substrate containing laminin, Sema3A, and/or PNN
GAGs and subsequently stainedwithIII tubulin for theneurites. Outgrowthmeasurement is presented as an averageof 10neurites per explant, 2–10 explants
per condition from two separate experiments. A,measurement of neurite outgrowth of DRG explants on 25g/ml PNN GAGs in combination with increasing
amounts of Sema3A. DRG explants cultured on PNN-GAGs showed a reduction in neurite length when compared with laminin control. Further reduction was
observed when the explants were cultured with increasing concentration of Sema3A (1:50 and 1:10) suggesting Sema3A confers a stronger inhibition upon
PNNGAGsonneurite inhibition. Increasing amounts of Sema3Ademonstrated adose-dependent inhibition.Data arepresentedasmean S.E.B, classification
of neurite outgrowth ability of the DRG explants according to the number of neurites per explant. Explants cultured on PNN GAGs showed a decrease in the
percentage of explants bearing 20 neurites. This inhibition was even stronger when the explants were cultured in the presence of both PNN GAGs and
Sema3A. Themajority of explants project less than three neurites. The data are presented asmean S.E. for each class. C, images of theDRG explants cultured
on “laminin,” “laminin plus PNN GAGs,” “laminin, PNN GAGs, Sema3A, and control antibody (MPB49V),” and “laminin, PNN GAGs, Sema3A, and anti-CS-E
antibody” (GD3G7). Scale bar equals 200 m. D, quantification of neurite outgrowth of the DRG explants culture with the presence of anti-CS-E antibody.
Explants cultured on PNN GAGs or Sema3A project significantly shorter neurites than the laminin control (1st to 3rd bars). A combination of PNN GAGs and
Sema3A leads to a stronger inhibitionon theoutgrowth (4thbar), and this inhibition is amelioratedwhen thePNNGAGswere treatedwithChABC (5thbar), Hep
I and III (to a lesser extent, bar 6) and anti-CS-E GD3G7 antibody. Treatmentwith controlMPB49V antibody does not remove the inhibition from the substrates.
n 60–100, mean S.D., two-tailed paired t test, ***, p 0.0001.
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GAG interactions in retaining Sema3A at the cell surface (25).
Our recent work in rat brains demonstrated that Sema3A is
retained at the surface of PNN-bearing neurons and is released
by ChABC injection into the brain. This indicates that Sema3A
is bound to CS-GAGs in the PNNs (1). In this study, we have
continued to characterize the nature of the GAGs, which are
responsible for the binding of Sema3A to the PNNs. The
Sema3A in brain tissue can be released by treatment with 1 M
NaCl or detergent buffer, indicating that it is attached to gly-
cans by moderate affinity charge interaction. To characterize
the binding, we first examined binding to glycans of known
sulfation pattern. Similar to our previous study, Sema3A bound
to heparin and CS-GAGs (25). However, not all forms of CS-
GAGs bind to Sema3A. CS-E and -B show strong interactions
in our ELISA, whereas CS-A, -C, and -D do not. With GAG
microarrays, the results are very similar, although less binding
to CS-B was observed, presumably due to differences in the
percentage of 2,4-disulfated CS in the CS-B derived from pig
skin compared with pig intestine. Moreover, the fact that CS-D
disulfated disaccharide units do not bind Sema3A is significant
because it indicates that the specific sulfation pattern defines
the binding site on glycans rather than the mere overall charge
of the molecule. Organization of the disaccharides into local
binding domains with specific affinity toward interacting pro-
teins has been described (41–43). In general, GAG-binding
proteins discriminate to various degrees between the different
GAG structures. Whereas the anti-coagulant effect of binding
of anti-thrombin 3 to heparin requires a specific organization of
sulfate groups, less specificity exists for some other protein-
GAG interactions (44), and several growth factors have been
shown to interact with variable structures and types of GAGs
(45). In previous work, we analyzed the composition of the dif-
ferent sulfate structures in the PNN fraction by disaccharide
analysis (10), showing that CS-B and CS-E disaccharides are
only responsible for 0.8 and 2% of the total PNNGAGs. Despite
this small percentage, our results indicate that CS-containing E
units in the PNNs are themain target for Sema3A binding. The
exact composition of the GAG structure responsible for
Sema3A interaction cannot be deduced from the present data.
Indeed, it is likely that a set of various GAG sequences that
include CS-E, and possibly CS-B, are able to interact with
Sema3A. Hence, we cannot totally exclude the contribution
from other CS-disaccharides in this interaction.
We have also assayed for the binding of Sema3A to PNN
GAGs, isolated by a sequential purification method from adult
brain (10). Sema3A showed a strong binding to the PNN frac-
tion, but almost no binding to the GAGs extracted in the solu-
ble or detergent-soluble fractions, which come from the diffuse
matrix throughout the CNS. This finding is consistent with our
hypothesis that the different sulfation composition in the dif-
ferent fractions may confer different binding properties to the
glycans.Our results demonstrate that aCS-E disaccharide-con-
taining structure (found inPNNs) is themain contributor to the
binding and that this binding could be blocked by an anti-CS-E
antibody. To further test the conclusion that Sema3A binds to
CS-containing E units, we digested brain tissue GAGs with two
sulfatases, measuring Sema3A release from the tissue. Diges-
tion with chondro-6-sulfatase, which removes all 6-O-sulfate
groups in the GAG chains and converts 4,6-disulfated E units
into 4-O-sulfatedAunits, released asmuch Sema3A asChABC.
The 4-sulfatase, which releases 4-O-sulfate groups from inter-
nalGalNAc-4-O-sulfate, but not fromCS-E (37), did not release
Sema3A. Overall, our results support the idea that the majority
of Sema3A is retained on the PNNs through binding to CSs
containing E disaccharide units. It would be interesting to
investigate the context of CS-E residues in the GAG chains and
also where these putative binding sites are located along the CS
chain.
We used three different Sema3As, namely Sema3A-AP,
Sema3A-GFP, and Sema3A-Fc, in our study to eliminate the
possibility that the reported binding results are due to any pos-
sible interference from the tag proteins. We also verify that the
observed binding was due to the expressed Sema3A but not the
presence of other proteins present in themedia/lysate (Figs. 2D
and 7B). Moreover, although Sema3A-AP and Sema-GFP are
collected and partially purified from culture media or cell
lysate, the Sema3A-Fc is of90% purity according to the sup-
plier’s information.
Binding to HSPGs—PNNs contain both CSPGs and HSPGs.
Themajority of PNNGAGs are of CS-type (70%), and the rest
is mainly HS and possibly also some keratan sulfate (10). We
therefore asked whether some of the Sema3A binding is due to
the presence of HSPGs. We treated the PNN GAGs with
ChABC or heparitinases before assaying for the Sema3A bind-
ing (Fig. 3B). Neither enzyme alone abolished Sema3A binding,
but a combination of the two led to a complete abolition of
binding, indicating that both types of GAG in the PNNs are
capable of interacting with Sema3A. However, only ChABC
and chondro-6-sulfatase released Sema3A from brain tissue,
and heparitinases were ineffective, suggesting that the majority
of Sema3A binding is to CS-GAG (Fig. 6). This is supported by
our recent work showing that ChABC injection into adult rat
brain completely abolishes the Sema3A staining around PNNs
(1). Taken together, Sema3A is capable of interacting with var-
ious GAGs, but our results indicate that the main contribution
to the interaction with PNNs is via the CS-E disaccharide units
in the CSs.
Effects of Sema3A-PNN GAG Binding—We explored the
response of adult DRG neurons to PNN GAGs in combination
with Sema3A (Fig. 8). The growth of DRG neurites was inhib-
ited in the presence of either PNN-GAGs or Sema3A alone, as
demonstrated in several in vitro systems using soluble Sema3A
(25, 46). The addition of Sema3A to PNNGAGs confers further
inhibition on the neurite outgrowth, both on neurite length and
number of neurites per explant. Our findings are in line with
other studies investigating the relationship between CSs and
Sema3A. Zimmer et al. (26) has shown that combining CSPG
and soluble Sema3A-Fc leads to a 10% increase in the repellent
activity in an in vitro stripemigration assay of cortical interneu-
rons during development. This suggests a combined effect of
CSs and Sema3A. However, the interaction with CS-GAGs was
not further characterized. In this work, we demonstrated that
the binding of Sema3A to CSs is likely to be mediated via the
CS-E units and that the addition of anti-CS-E antibody GD3G7
in the DRG culture relieved the outgrowth inhibition from the
addition of Sema3A (Fig. 8, B and C). The possible additive
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effect of Sema3A with PNN-GAGs could be attributed by the
independent signaling pathways these two families of mole-
cules are eliciting. Whereas Sema3A signals through the neu-
ropilin-1 (NP-1)/plexin receptor complex (47–50), the inhibi-
tion from CSs in the PNN-GAGs can be triggered via the
recently identified receptors, such as protein-tyrosine phos-
phatase-, leukocyte common-related phosphatase, Nogo
receptors, or contactin pathways (51–54). It is possible that the
simultaneous presentation of both Sema3A and CSs on the neu-
ronal surface confer stronger inhibitory properties to the PNNs,
which will trigger both inhibitory signaling pathways in the
incoming growth cones and therefore exclude new connections
from PNN-surrounded neurons in the adult CNS.
The role of Sema3A in the adult CNS is not understood.
Sema3A expression is sustained after birth, but at a lower level
in several areas of theCNS (23).However, the receptor complex
NP-1plexin for Sema3A are both widely expressed in the adult
CNS (47–50). The effect of Sema3A has been suggested to be
tuned by heparin, facilitating stronger binding to NP-1 (25).
Indeed, Sema5A, another member from the Sema family, acts
as both positive and negative guidance cue in neuronal out-
growth depending on its interaction with HS or CS (55). Our
observation that Sema3A is presented on PNNs, coupled with
the established role of PNNs in controlling plasticity, suggests
that PNNs may exert their effect partly through Sema3A. The
PNNs may utilize the Sema3A in controlling neurite growth
and synapse dynamics. This hypothesis has been tested by
expressing NP-1-fc in adult visual cortex, leading to reactiva-
tion of ocular dominance plasticity. However, it is unlikely that
all the effects of PNNs are mediated through this mechanism.
Recent reports have implicated the role of PNNs in the modu-
lation of synapses through AMPA receptor mobility, which is
unlikely to involve Sema3A (56, 57). Moreover, several CSPG
receptors, such as protein-tyrosine phosphatase-, contactin,
and Nogo receptor 3, are also widely expressed in the CNS
(51–54). They may mediate growth inhibition by directly bind-
ing to the CS GAGs (27).3 However, the specific interaction of
Sema3A to CS-E units suggests that an anti CS-E antibody or
other CS-E blocker may aid in restoring plasticity and promot-
ing recovery of the CNS after injury.
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